Author: Customer Service

Miami, FL, Dec. 31, 2025 (GLOBE NEWSWIRE) — NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced plans to launch a shareholder rewards program delivering a tangible, real-world benefit through its EzFill platform. Once launched, shareholders will receive a digital fuel-discount coupon token deposited directly into their EzFill mobile app accounts. Upon receipt, the token may be redeemed for one fueling event at a single location and can be applied across multiple vehicles or equipment, including passenger vehicles, commercial fleets, construction equipment, and marine vessels. The coupon token will also be transferable within the EzFill app, allowing shareholders to share the benefit with friends or family while introducing new users...

ST. PETERSBURG, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) — BayFirst Financial Corp. (NASDAQ: BAFN) (“BayFirst” or “Company”), parent company of BayFirst National Bank (“Bank”) today announced that it will report its fourth quarter results after the market close on Thursday, January 29, 2026. Management will host a conference call on Friday, January 30, 2026, at 9:00 a.m. ET to discuss the results. The call will also be broadcast live via the internet. Interested investors may listen to the call live under the Investor Relations tab at www.bayfirstfinancial.com. Investment professionals are invited to dial (800) 549-8228 to participate in the call using Conference ID 15602. A replay of the call will be available for one year at www.bayfirstfinancial.com. About BayFirst Financial Corp. BayFirst Financial Corp. is a registered bank holding...

LAKEWOOD, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) — First Commerce Bancorp, Inc. (the “Company”), (OTC: CMRB), the holding company for First Commerce Bank (the “Bank”), today announced the completion of a private placement of a $40.0 million 7.75% Fixed-to-Floating Rate Subordinated Note due December 30, 2035 (the “Note”). The Note will initially bear interest at a fixed annual rate of 7.75%, payable semi-annually in arrears, until December 30, 2030, and will reset quarterly thereafter to the then current three-month SOFR rate plus 432 basis points, payable quarterly in arrears. Beginning on December 30, 2030, the Note may be redeemed, in whole or in part, at the Company’s option subject to any required regulatory approval, on any scheduled interest payment date. Prior to December 30, 2030, the Note may be redeemed, in whole but not...

Vancouver, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company had previously announced that it was notified by Nasdaq on December 4, 2025, that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s common...

 EXEL IndustriesA French Société Anonyme with a share capital of €16,969,750Registered office: 54, rue Marcel Paul – 51206 Epernay Cedex – FranceReims Companies Register (RCS): No. 095 550 356 Number of shares and voting rights Article 223-16 of the AMF regulationDate Total number of shares comprising the share capital Total number of voting rightsNovember 30, 2025 6,787,900  Theoretical voting rights: 9,891,515Exercisable voting rights*: 9,886,050  * After deduction of shares without voting rightsAttachmentEXEL Industries Droits de vote 2025.11.30_EN

Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS’ global manufacturing capacity, strengthens supply-chain resilience, and supports an expected improvement of approximately 20 percentage points in gross margin ahead of planned U.S. market entry NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new strategic manufacturing partnership with Syrma Johari MedTech Ltd. (“Syrma Johari”), a globally recognized medical device engineering and manufacturing organization with over 45 years of experience, to support and scale the production of its Intelligent Fingerprinting...

SARASOTA, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) — Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: DJT) (“Trump Media”), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, today announced plans to distribute a new digital token to its shareholders in partnership with Crypto.com. The distribution is expected to leverage Crypto.com’s cutting-edge technology, including the high performance, interoperable Cronos blockchain designed for speed, scalability, and seamless connectivity between networks. Trump Media anticipates that, beginning in the near future, each ultimate beneficial owner will be eligible to receive one of the new digital tokens per whole share of DJT, with various rewards being made available to token holders periodically throughout...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a Phase 1/2 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking regulatory clearance to initiate clinical trials of CYPS317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of moderate to severe psoriasis. This IND filing represents a major advancement for FibroBiologics’ chronic inflammatory disease pipeline and follows a series of positive IND-enabling preclinical results demonstrating the potential of fibroblast...

SAN CLEMENTE, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) — ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 12-15, 2026. ICU Medical’s presentation will be on Wednesday, January 14, 2026 at 1:30 p.m. PT (4:30 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, January 14, 2026. The presentation will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay. About ICU Medical ICU Medical (Nasdaq: ICUI) is a global leader in...

Bagsværd, Denmark, 31 December 2025 – Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent. Novo Nordisk is pleased that the Court has upheld the Beijing IP Court ruling recognising the validity of the semaglutide compound patent. “This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,” said Mike Doustdar, president and CEO of Novo Nordisk. “This decision also strengthens confidence for foreign companies’ sustainable development in China and will motivate further development and introduction of innovative medicines for the benefit of patients.” Semaglutide is a novel, long-acting, glucagon-like peptide-1 (GLP-1) analogue invented and developed by Novo Nordisk. It is the...